Hypertension Vaccine may be a boon to millions in developing world

References

• World Health Organization. Global status report on noncommunicabledisaeses 2010. Geneva: WHO; 2011.
   Google Scholar
• Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224 - 60; http://dx.doi.org/10.1016/S0140-6736(12)61766-8; PMID: 23245609
   PubMed Web of Science ®Google Scholar
• Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97:596 - 601; http://dx.doi.org/10.1161/01.CIR.97.6.596; PMID: 9494031
   PubMed Web of Science ®Google Scholar
• Institute of Health Metrics & Evaluation. GBD 2010 change in leading causes and risks between 1990 and 2010. (Accessed on July 21, 2013)Available from: http://www.healthmetricsandevaluation.org/gbd/visualizations/gbd-2010-change-leading-causes-and-risks-between-1990-and-2010?metric=DALY
   Google Scholar
• Basu S, Millett C. Social epidemiology of hypertension in middle-income countries: determinants of prevalence, diagnosis, treatment, and control in the WHO SAGE study. Hypertension 2013; 62:18 - 26; http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01374; PMID: 23670299
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Health Observatory (GHO): Raised blood pressure situation and trends. Geneva: WHO; 2013. (Accessed April 24, 2013). Available from: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/
   Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217 - 23; PMID: 15652604
   PubMed Web of Science ®Google Scholar
• Ogah OS, Okpechi I, Chukwuonye II, Akinyemi JO, Onwubere BJC, Falase AO, et al. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: A review. World J Cardiol 2012;4:327–40. (Accessed on August 28, 2013)Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530788/
   Google Scholar
• Krishnan A, Garg A, Kahandaliyanage A. Hypertension in the South East Asia Region: an overview. Regional Health Forum 2013;17:7-14.
   Google Scholar
• Devi P, Rao M, Sigamani A, Faruqui A, Jose M, Gupta R, Kerkar P, Jain RK, Joshi R, Chidambaram N, et al. Prevalence, risk factors and awareness of hypertension in India: a systematic review. J Hum Hypertens 2013; 27:281 - 7; http://dx.doi.org/10.1038/jhh.2012.33; PMID: 22971751
   PubMed Web of Science ®Google Scholar
• Reddy KS. Regional case studies–India. Nestle Nutr Workshop Ser Pediatr Program. 2009;63:15-24; discussion 41-6, 259-68.
   Google Scholar
• World Health Organization. World Health Day - 7 April 2013. Geneva: WHO; 2013.
   Google Scholar
• Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011; 11:865 - 72; PMID: 22051890
   PubMed Web of Science ®Google Scholar
• Gaziano TA, Bitton A, Anand S, Weinstein MC, International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens 2009; 27:1472 - 7; http://dx.doi.org/10.1097/HJH.0b013e32832a9ba3; PMID: 19474763
   PubMed Web of Science ®Google Scholar
• Osamor PE, Owumi BE. Factors associated with treatment compliance in hypertension in southwest Nigeria. J Health Popul Nutr 2011; 29:619 - 28; PMID: 22283036
   PubMed Web of Science ®Google Scholar
• Mahal A, Karan A, Engelgau M. 3. The economic implications of non-communicable disease for India. Health, nutrition and population (HNP) discussion paper. Washington: The World Bank; 2010 (Accessed on May 2013). Available from: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/EconomicImplicationsofNCDforIndia.pdf
   Google Scholar
• Engelgau MM. Sameh El-Saharty, Kudesia P, Rajan V, Rosenhouse S, Okamoto K. Capitalizing on the demographic transition: tackling noncommunicable diseases in South Asia. Washington DC: World Bank;2011. (Accessed on June 23, 2013). Available from: http://www-wds.worldbank.org/external/default/WDSContentServer/IW3P/IB/2011/08/17/000333038_20110817004056/Rendered/PDF/622600REPLACEM0blic00use0same0info0.pdf
   Google Scholar
• Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007; 50:991 - 7; http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.095497; PMID: 17954719
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute, National Institutes of Health, U. S. Department of Health and Human Services. JNC 7 Express. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda, MD: National Institutes of Health; 2003. NIH Publication No. 03-5233.
   Google Scholar
• Sabaté E, ed. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
   Google Scholar
• Redwood H. Hypertension, society and public policy. Eur Heart J Suppl 2007; 9:B13 - 8; http://dx.doi.org/10.1093/eurheartj/sum003
   Google Scholar
• Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich) 2003; 5:Suppl 2 3 - 13; http://dx.doi.org/10.1111/j.1524-6175.2003.02463.x; PMID: 12826765
   PubMedGoogle Scholar
• Phisitkul S. CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs 2009; 10:269 - 75; PMID: 19333885
   PubMed Web of Science ®Google Scholar
• Ou X, Guo L, Wu J, Mi K, Yin N, Zhang G, Li H, Sun M. Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle. Hum Vaccin Immunother 2013; 9:1191 - 9; http://dx.doi.org/10.4161/hv.23940; PMID: 23412424
   PubMed Web of Science ®Google Scholar
• Goldblatt H, Haas E, Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians 1951; 64:122 - 5; PMID: 14884242
   PubMedGoogle Scholar
• Slater EE, Corvol P, Menard J, Burton J, Hartley LH. Antisera to human renin normalize renin-dependent hypertension in the monkey: therapeutic implications. Clin Exp Hypertens A 1984; 6:923 - 37; http://dx.doi.org/10.3109/10641968409044047; PMID: 6203672
   PubMed Web of Science ®Google Scholar
• Wood JM, Heusser C, Gulati N, Forgiarini P, Hofbauer KG. Monoclonal antibodies against human renin. Blood pressure effects in the marmoset. Hypertension 1986; 8:600 - 5; http://dx.doi.org/10.1161/01.HYP.8.7.600; PMID: 3013776
   PubMed Web of Science ®Google Scholar
• Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect of experimental renal hypertension. J Exp Med 1964; 119:425 - 32; http://dx.doi.org/10.1084/jem.119.3.425; PMID: 14129713
   PubMed Web of Science ®Google Scholar
• Helmer OM. Studies on renin antibodies. Circulation 1958; 17:648 - 52; http://dx.doi.org/10.1161/01.CIR.17.4.648; PMID: 13523774
   PubMed Web of Science ®Google Scholar
• Macdonald GJ, Louis WJ, Renzini V, Boyd GW, Peart WS. Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res 1970; 27:197 - 211; http://dx.doi.org/10.1161/01.RES.27.2.197; PMID: 4318416
   PubMed Web of Science ®Google Scholar
• Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, Ménard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 1987; 84:4346 - 50; http://dx.doi.org/10.1073/pnas.84.12.4346; PMID: 3108891
   PubMed Web of Science ®Google Scholar
• Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990; 81:1899 - 910; http://dx.doi.org/10.1161/01.CIR.81.6.1899; PMID: 2188756
   PubMed Web of Science ®Google Scholar
• Reade R, Michel JB, Carelli C, Huang H, Baussant T, Corvol P. [Immunisation of spontaneously hypertensive rats against angiotensin I]. Arch Mal Coeur Vaiss 1989; 82:1323 - 8; PMID: 2510667
   PubMedGoogle Scholar
• Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, Martin H, Morgan PJ, Rushton A, Bennett T, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 2000; 129:1178 - 82; http://dx.doi.org/10.1038/sj.bjp.0703178; PMID: 10725266
   PubMed Web of Science ®Google Scholar
• Downham MR, Auton TR, Rosul A, Sharp HL, Sjöström L, Rushton A, Richards JP, Mant TG, Gardiner SM, Bennett T, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003; 56:505 - 12; http://dx.doi.org/10.1046/j.1365-2125.2003.01926.x; PMID: 14651724
   PubMed Web of Science ®Google Scholar
• Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004; 107:167 - 73; http://dx.doi.org/10.1042/CS20030381; PMID: 15040783
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of angiotensin therapeutic vaccine in subjects with mild to moderate hypertension. (Accessed May 4, 2013). Available from: http://clinicaltrials.gov/show/NCT00702221
   Google Scholar
• Zhu F, Liao YH, Liudong L, Wei YM, Wang M, Chen M, et al. Observation of long-term efficacy and safety of an ATR12181 vaccine against hypertension in SHR. Circulation. 2006;114 (18 suppl):II-575. Abstract 2753. (Accessed May 3, 2013). Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_575-c
   Google Scholar
• Zhu F, Liao YH, Li LD, Cheng M, Wei F, Wei YM, Wang M. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006; 3:107 - 14; PMID: 16696897
   PubMed Web of Science ®Google Scholar
• Ou X, Guo L, Wu J, Mi K, Yin N, Zhang G, Li H, Sun M. Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle. Hum Vaccin Immunother 2013; 9:1191 - 9; http://dx.doi.org/10.4161/hv.23940; PMID: 23412424
   PubMed Web of Science ®Google Scholar
• Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007; 25:63 - 72; http://dx.doi.org/10.1097/HJH.0b013e32800ff5d6; PMID: 17143175
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Müller P, Jennings GT, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371:821 - 7; http://dx.doi.org/10.1016/S0140-6736(08)60381-5; PMID: 18328929
   PubMed Web of Science ®Google Scholar
• Hong F, Quan WY, Pandey R, Yi S, Chi L, Xia LZ, Yuan M, Ming L. A vaccine for hypertension based on peptide AngI-R: a pilot study. Int J Cardiol 2011; 148:76 - 84; http://dx.doi.org/10.1016/j.ijcard.2009.10.027; PMID: 19932924
   PubMed Web of Science ®Google Scholar
• Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, Wang M, Lin J, Yu X, Zhou Z, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension 2013; 61:408 - 16; http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.201020; PMID: 23184378
   PubMed Web of Science ®Google Scholar
• Bairwa M, Rajput M, Khanna P, Rohilla R, Verma R, Chawla S. Malaria vaccine: a bright prospect for elimination of malaria. Hum Vaccin Immunother 2012; 8:819 - 22; http://dx.doi.org/10.4161/hv.20145; PMID: 22739688
   PubMed Web of Science ®Google Scholar
• World Health Organization. Introducing a vaccine: policy and programme considerations. (Accessed on September 28, 2013)Available from: http://www.who.int/nuvi/Vaccine_intro_resources/en/
   Google Scholar
• Shetty P. Vaccine trial’s ethics criticized. Nature 2011; 474:427 - 8; http://dx.doi.org/10.1038/474427a; PMID: 21697918
   PubMed Web of Science ®Google Scholar
• Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol 2012; 33:7 - 12; http://dx.doi.org/10.4103/0971-5851.96961; PMID: 22754202
   PubMedGoogle Scholar